NASDAQ:TNDMTandem Diabetes Care Stock Price, Forecast & News

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TNDM stock has increased by 54.9% and is now trading at $102.76. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tandem Diabetes Care.

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Tandem Diabetes Care.

Tandem Diabetes Care will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Tandem Diabetes Care Inc (NASDAQ:TNDM) released its quarterly earnings results on Thursday, April, 30th. The medical device company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.07. The medical device company had revenue of $97.90 million for the quarter, compared to analysts' expectations of $84.49 million. Tandem Diabetes Care had a negative net margin of 4.22% and a negative return on equity of 9.39%. The firm's revenue for the quarter was up 49.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.40) earnings per share. View Tandem Diabetes Care's earnings history.

Shares of Tandem Diabetes Care reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care updated its second quarter 2020 After-Hours earnings guidance on Thursday, April, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $85 million, compared to the consensus revenue estimate of $85.26 million.

12 brokers have issued 1 year target prices for Tandem Diabetes Care's stock. Their forecasts range from $75.00 to $125.00. On average, they anticipate Tandem Diabetes Care's stock price to reach $97.23 in the next year. This suggests that the stock has a possible downside of 5.4%. View analysts' price targets for Tandem Diabetes Care.

Press coverage about TNDM stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tandem Diabetes Care earned a news impact score of -1.2 on InfoTrie's scale. They also assigned headlines about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Tandem Diabetes Care.

Some companies that are related to Tandem Diabetes Care include Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Novocure (NVCR), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Irhythm Technologies (IRTC), NuVasive (NUVA) and Inspire Medical Systems (INSP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Verizon Communications (VZ), Crispr Therapeutics (CRSP) and Roku (ROKU).

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Tandem Diabetes Care's stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.01%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View institutional ownership trends for Tandem Diabetes Care.

TNDM stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, and Leigh Vosseller. View insider buying and selling activity for Tandem Diabetes Care.

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TNDM stock can currently be purchased for approximately $102.76.

Tandem Diabetes Care has a market capitalization of $6.18 billion and generates $362.30 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. Tandem Diabetes Care employs 1,043 workers across the globe.

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]